Educational Advisory Board

Dr. Axel Anderl

Vienna / AT

Antitrust / General Data Protection (GDPR)

Axel Anderl joined DORDA in 2005 and became managing partner in 2018. He heads the IT/IP, Media and Unfair Competition team, which has been the recipient of multiple awards, as well as DORDA’s Digital Industries Group. His practice group is continuously named as leading in its field by all internationally relevant lawyer directories. He and his team are unique in Austria to being continuously ranked in Tier 1 in IT, IP, and Data Protection by both, Chambers Europe and Legal 500 for several years running. Additionally, Axel is listed in the Legal 500 Hall of Fame for TMT (Technology, Media, Telecoms). The latter is achieved by being ranked as leading individual for at least six years in a row. Such an amount of (repeated) awards and top placements is unmatched in Austria. Axel mainly advises on matters regarding software law, including copyright and patents, outsourcing, media law, trademarks, unfair competition and e- commerce. His focus is on complex outsourcing- and IT-projects, particularly in the regulated banking and insurance sector.

Languages: English, German

Education: University of Vienna (Dr iur 2005), University of Vienna (LL.M. 2001)

Dr. Heinrich Kühnert

Vienna / AT

Antitrust / General Data Protection (GDPR)

Dr. Heinrich Kühnert joined DORDA in 2016. He is a partner and heads the firm’s Antitrust and competition practice group. Dr. Kühnert advises clients on all aspects of Austrian and European competition law including merger control, antitrust, abuse, and state aid. He has broad experience in the healthcare and pharmaceutical sector, as well as the energy, transport, telecom, media, healthcare, mechanical engineering and retail sectors. As member of the Studienvereinigung Kartellrecht, he acts as Austrian expert of the European Competition and Regulatory Law Review.

Dr. Kühnert regularly publishes and lectures on competition law topics.

Languages: English, French, German

Education: University of Vienna (Dr iur 2004) and University of Oxford (M. Jur. 2004)

Publications: Sales Restrictions in a Production Joint Venture: Return of the Formal Approach (European Competition and Regulatory Law Review, 2018)

The International Comparative Legal Guide to: Merger Control 2020 (Global Legal Group, 2019)

Mag. Mag. Nino Tlapak

Vienna / AT

Antitrust / General Data Protection (GDPR)

Mag. Nino Tlapak joined DORDA’s IT and Data Protection team in 2013 and is a partner since 2021. He focuses on data protection and IT-security law. Further areas of practice include e-commerce and outsourcing. Mag. Tlapak is particularly well known for his data protection activities and also functions as coordinator of DORDA’s data protection unit as well as external data protection officer for selected clients. In addition, he regularly publishes articles in the field of data protection and holds lectures on the same topic at the Danube- University Krems (Data Protection and Privacy – certified program), the technical colleges FH Technikum Wien and FH Campus Wien as well as the IT-Law LL.M. postgraduate program of the University of Vienna.

Languages: English, German

Education: University of Vienna (LL.M. 2013), University of Vienna (Mag iur 2012)

Rankings: Next Generation Partner (The Legal 500, 2022); Band 4 (Chambers Europe, 2022)

Prim. Priv. Doz. Dr. Georg Delle-Karth

Vienna / AT

Cardiology / Cardiovascular medicine

Curriculum Vitae Prim. Priv. Doz. Dr. Georg Delle Karth

Krankenhaus Hietzing mit Neurologischem Zentrum Rosenhügel
Wolkersbergenstrasse 1, A-1130 Vienna
Date of birth: 3 February 1968
Citizenship: Austria

E-Mail: georg.delle-karth@wienkav.at
Phone: (+43 1) 80110-2511
Fax: (+43 1) 80110-2687

Hospital Appointments

Since Aug. 2014                Director of the 4th Department of Medicine, Cardiology at the KH Hietzing, Vienna

Since 2014                         Head of the Karl Landsteiner Institute for Cardiovascular and Intensive Care research

March -Aug. 2014            Director, Catheterization Laboratory, AKH, Medical University of Vienna

Feb.2009- Feb. 2014       Co-Director, Catheterization Laboratory, AKH, Medical University of Vienna

Jan.-April 2007                „Senior Advisor Cardiology „Prince Court Medical Center”, Kuala Lumpur, Malaysia

2003-2008                       Co-Director, Cardiac Intensive Care Unit AKH, Medical University of Vienna

Academic Appointments

2007      Professor of Medicine, Medical University of Vienna

Diploma

2006      Board Certification: Cardiology

2004      Board Certification: Medical Intensive Care

2000      Board Certification: Internal Medicine

Academic Career

2007      Venia docendi, Medical University of Vienna

Habilitation treatise: The cardiologic, critically ill patient

1993      MD Doctoral thesis: The chromosomal mechanism of the translocation t 14:18 in lymphomas

1987-1993          Medical School at the University of Vienna, two awards for outstanding performance

Additional diploma

2009      ERC Advanced life support–Provider Course

2002      Certification for transthoracic Echocardiography by the Austrian Society of Echocardiography

Publications, studies and lectures

Over 60 publications in medical journals with peer review http://www.ncbi.nlm.nih.gov/pubmed/?term=delle+karth+g+or+karth+gd)

Numerous clinical studies as principal and co-investigator

Over 70 national and international lectures

Main Scientific Topics

Acute coronary syndromes, cardiogenic shock, antiplatelet therapy, PCI-techniques

Teaching

Diploma thesis advisor, ongoing lectures and educational activities at the Medical University of Vienna and out of University

Memberships

2012-2016          Committee member (congress organization, educational) Acute Cardiac Care-Association European Society of Cardiology (ESC)

Since 2012          Acute Cardiac Care Association, ESC

2008-10              Head, Working group Cardiovascular Intensive Care, Austrian Society of

Cardiology

Since 2008          Working group Interventional Cardiology, Austrian Society of Cardiology

Since 2002          Nucleus Member of the Working Group Cardiovascular Intensive Care, Austrian Society of Cardiology

2005-ongoing     Member of the guideline committee „Cardiogenic shock“ German & Austrian Society of Cardiology

Since 2002          Austrian Society of Cardiology – ESC

Univ. Prof. Dr. Martin Grabenwöger

Vienna / AT

Cardiology / Cardiovascular medicine

Head of the Department of Cardiovascular Surgery of the Hospital North

Head of the Karl Landsteiner Institute for Cardiac and Vascular Surgery

Past President of the European Society of Cardiothoracic Surgery (EACTS)

Professor of Cardiac Surgery Sigmund Freud University of Vienna (SFU)

Education and previous career

1981 – 1988: Medical studies at the University of Vienna

03.02.1988: Doctorate in Medicine, University of Vienna

1987 – 1989: Associate at the Ludwig Boltzmann Institute for Cardiac Surgery (intensive care for calves after total heart replacement).

Jan.1989- Dec.1990: Employment as scientific assistant in the project “Endothelialization of biological heart valves”
Freelancer in the endothelial cell laboratory of the II. Chir. Univ.-Klinik (Prof. Dr. E. Wolner) and the Institute of Micromorphology and Electron Microscopy (Prof. Dr. P. Böck).

July 1991- April 1994: Contract Assistant at the II. Surgeon. University Hospital Vienna (Prof. Dr. E. Wolner)

May 1994 – Sept. 1995: Assistant to the Department f. Cardiac Thoracic Surgery AKH Vienna

Oct. 1995 – Sept. 1996: Year of absence: assistant to the heart surgery in the hospital of the state capital St. Pölten (Dr. H. Kassal).

Since 01.10. 1996: Assistant to the Department f. Cardiothoracic Surgery AKH Vienna (Prof. Dr. E. Wolner)

15.11.1996: Specialist in surgery

January 1997 – Sept. 2004: Senior Physician at the Department of Cardiothoracic Surgery, University of Vienna

Okt.1997- Dec.1997: Senior physician at the heart surgery in Frankfurt (Prof. Dr. A. Moritz)

02.03.1998: Teaching authorization as university lecturer for surgery

Nov. 15, 1999: Specialist in cardiac surgery

February 2001: Baylor College of Medicine (Joseph Coselli, MD) Focus: Thoracic aneurysm surgery

May -June 2002: stay at the Department of Vascular Surgery at the Salzburg State Hospital (Prof. Dr. H. Magometschnigg)

January 31, 2003: Additive specialist for vascular surgery

1996 – 2004: Senior Physician at the Department of Cardiothoracic Surgery at the University of Vienna; Team leader of the aortic aneurysm program and electrophysiology

Since October 2004: Head of the Department of Cardiovascular Surgery, KH Hietzing

Since April 2019: Head of the Department of Cardiovascular Surgery, KH Nord

Andrea Podczeck-Schweighofer

Vienna / AT

Cardiology / Cardiovascular medicine

Andrea Podczeck-Schweighofer, MD

UNIVERSITY STUDIES

1972/1973    University of Bonn/Germany, Studies in Social Science

1973 – 1976 University of Bonn/Germany, Studies in Medicine

1976 –1979  University of Vienna, Studies in Medicine

M.D.  December 21^st, 1979

HOSPITAL ACTIVITIES

1980 – 1982 Wilhelminenspital/ Vienna, General Medicine

1982 – 1985 Wilhelminenspital (3^rd Medical Dept, Prof. Steinbach); Training in Internal Medicine/ Cardiology

1985 –  1986 University Hospital Duesseldorf/Germany (Prof. Loogen, Prof. Breithradt); Training in Cardiology

1987               Termination of Internal Medicine Training

Since 1987    leading position at 3^rd Medical Dept/cardiology at Wilheminenspital/Vienna

1989 – 1990 additional training in Cardiology

1990 – 1994 additional training in Intensive Care Medicine

December 1995   “Venia docendi”  University of Vienna

SPECIAL TRAINING

1984 Bartholomew´s Hospital London/UK (Prof. John Camm); Invasive and non-invasive cardiac electrophysiologic evaluation of arrhythmias

1986 –1987   University Hospital of Duesseldorf/Germany (Prof. Gunter Breithardt); Invasive electrophysiologic stuies in patients with arrhythmias, ablation, procedures, basic research in the mechanisms of arrhythmias

1995  University Hospital of Muenster / Germany (Prof. G. Breithardt); Invasive cardiac electrophysiology of arrhythmias

2003 University Hospital of Vienna (Prof. G. Maurer); Cardiac catheterization

LEADING POSITIONS

Intensive Care Unit, 3^rd Medical Dept/ Cardiology Wilhelminenspital

ICD Outpatient Clinic

3^rd Medical Dept/Cardiology    Outpatient Clinic

Since September 1^st, 2004     Head of 5^th Medical Dept/Cardiology Kaiser Franz Josef- Spital/Sozialmedizinisches Zentrum Sued, Vienna

Since 2016 Professor in Cardiology at the Sigmund Freud Medical University Vienna

ORGANISATION AND CO-ORGANISATION of numerous meetings, congresses in Cardiology

MEMBERSHIPS AND SCIENTIFIC FUNCTIONS

1993   Member of “Gesellschaft der Aerzte Wien”

Austrian Delegate to the Working Group for Cardiac Pacing and Electrophysiology of the European Society of cardiology (EWGCP)

2002 Staff Member of the Austrian Cardiac Society

2015: President elect of the Austrian Society of Cardiology

Heinz Weber

Vienna / AT

Cardiology / Cardiovascular medicine

Prim. Univ.-Prof. Dr. Heinrich Weber

MD, FESC, FACC

• Born in Vienna, Austria, EU
• May 1973: MD, Medical School of the University of Vienna meduniwien.ac.at
• 1973-76 GP-Training:  Kaiserin Elisabeth Hospital, and several other Viennese City Hospitals.
• 1976-2003 University of Vienna – Medical Faculty/ AKH (Vienna General Hospital, akhwien.at )
• 1976 – 1980 Training in General Internal Medicine:
  • Kardiologischen Univ.-Klinik, Dir. Univ.-Prof. Dr. F. Kaindl
  • Medizinischen Univ.-Klinik, Dir. Univ.-Prof. Dr. G. Geyer
• 1980 – 1987 Training in Cardiology and Intensive Care Medicine
  • Staff member at the Kardiologische Univ.-Klinik since 1982
  • 1986 PhD, Assoc. Prof. (Habilitation and Univ.-Dozent )
  • 1987 Specialist in Cardiology
• 1987 – 1994 Staff Member of the Univ.-Clinic Inter. II – Depmnt. of Cardiology
  • 1991 tit. Ao Univ.-Professor of Internal Medicine
  • 1992 Specialist of Intensive Care Medicine
  • Responsibilities
    • 7 years consultant
    • 3 years Director of the Intensive Care Unit (ICU) 13H3, AKH
    • 1 year Vice-Director of the Catheter-Labs (4 biplane devices), AKH.
  • 1994 – 2003 First Director (Primarius) of the Med. Dpt. Cardiology, Kaiser Franz Josef Hospital in Vienna ( http://www.wienkav.at/kav/kfj )
  • 2004 – 31.1.2013 Director of the 1st Medical Department, Donauspital (Danube-Hospital), SMZ-Ost ( http://www.wienkav.at/kav/smz/ )

Medical Training:

• Training in invasive and interventional Cardiology:
  • Diagnostic: More than 20 years experience in diagnostic investigations of the heart, including several thousand Coronary Angios.
  • Interventions:
    • More than 1.800 PTCAs since 1988 incl. many complexed multi-vessel procedures, 90% Stent-implantations, (50% DES).
    • Intra-coronary Ultrasound (IVUS) plus virtual histology (VH).
    • 1993 Coronary-Angioscopies (100 cases).
    • PTCA -Courses (Frankfurt 1988, Toulouse 1990 and 1991, Jerusalem, Madrid, Milano 2000, Lausanne 2003, Lugano 2006, Barcelona 2008)
    • Experience with FFR and OCT (optical Coherenz-Tomographie)
    • Experience with „non-invasive“ Coronary-Angiography (Multislice CT incl.  Calzium-Scoring).
  • Elektrophysiology
    • 400 diagnostic and therapeutic Procedures of different nature.
    • Programmed Ventricular Stimulations.
    • Electrophysiology-Trainings Courses at St. Georgs Hospital, London (1990, 1991 Prof. Camm)
  • Experience in Intensive Care Medicine
    • Director of the Intensive Care Unit (ICU) 13H3, AKH from 1991 – 1994 (8 ICU beds)
      • 96 Beds at 3 wards,
      • ICU with 12 Intensive-Positions
      • Catheter-Labor (biplane device)
      • Electrophysiologic Labor
      • 32 MDs, among them 18 Specialists of Internal Medicine, Cardiology, Intensive Care Medicine and Angiology.
      • Special OPDs for PM, ICDs, Angiology etc.

Scientific Activities:

About 200 Publications, many of them in peer reviewed Journals dealing with Rhythmology (Longterm-ECG, Pacemaker, ICD, PV-Stimulations, antiarrhythmic drugs etc.), acute MI (STEMI in Vienna, in Austria, OCT, IVUS etc), in Resuscitation (Book about Emergency Medicine, 3 Edit.), Health economy, Epidemiology, participation in many MC RCTs relating to anticoagulation and lysis Therapy versus acute interventions. Many oral presentations, invitations and chairmanships (s. publication list) until today.

International Activities:

• Fellow of the European Society of Cardiology (FESC) ( www.escardio.org )
• Fellow of the American College of Cardiology (FACC) ( www.acc.org )
• Diploma of a “European Cardiologist” (2002)
• President of the Austrian Cardiac Society 1999/2000 (Österr. Kardiologischen Gesellschaft www.atcardio.org )
• Board member of the Austrian Cardiac Society 1998 – 2002
• Honorary Member of the Slovak Cardiac Society
• Board Member of the Viennese Medical Association (Gesellschaft der Ärzte in Wien www.billrothhaus.at )
• Vice-President of the Viennese Red Cross 2004 – 2012 ( http://www.w.roteskreuz.at )
• President of the UEMS-Cardiology Section 1998-2002 (Union Medicine Europeene Specialistes, http://www.uems.net )
• Founding-Chairman of EBAC (European Board for accreditation in Cardiology, ( www.ebac-cme.org ) 1999,.
• Co-Chairman of the EBSC (European Board for the Speciality of Cardiology), (s.o., http://www.cardiology-accreditation.org/ ).
• UEMS-Cardiology Section ( www.uems-cardio.eu ) Member of the Executive Commitee since 1998
• EBAC ( www.ebac-cme.org ): Member of the Advisory Commitee
• European Cardiology Society Foundation ( www.e-cs-f.org ) – Chairman of the Council
• Member of the Scientific Board of the Austrian Academy of Physicians (www.arztakademie.at)

Bernd Rosenkranz

Cape Town / ZA

Clinical Pharmacology

Prof Dr. med. Bernd Rosenkranz, FFPM

Prof Bernd Rosenkranz holds a medical degree from the University of Düsseldorf, is board certified Clinical Pharmacologist in Germany and South Africa, and Fellow of the Faculty of Pharmaceutical Medicine (FFPM). In 1994, he qualified as university lecturer (habilitation) at the Medical Faculty of the Philipps University Marburg with the venia legendi for Clinical Pharmacology; in 2001 he received the venia legendi for Clinical Pharmacology from the Medical Faculty, Humboldt University Berlin (Charité).

He spent 23 years in industry, as Director of Clinical Pharmacology at Hoechst/Hoechst Marion Roussel in Germany, France and USA, Chief Medical Officer at 3ClinicalResearch in Berlin/Hennigsdorf, Germany, and Vice President Clinical Development at Jerini, Berlin, Germany, where he was responsible for the world-wide clinical programme of icatibant in hereditary angioedema. In 2008, he was appointed Professor and Head of the Division of Clinical Pharmacology (Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa) from which he retired in 2016. In 2010, he established a postgraduate programme in Pharmaceutical Medicine / Medicines Development which received recognition as Centre of Excellence in 2014 by the PharmaTrain Federation.

Bernd Rosenkranz is co-founder and President of the Fundisa African Academy of Medicines Development, board member of the South African Society for Basic and Clinical Pharmacology (SASBCP), and secretary of the College of Clinical Pharmacologists (Colleges of Medicine of South Africa), He is member of various international organisations, such as the International Committee of the UK Faculty of Pharmaceutical Medicine, the Membership Committee of the International Union of Basic and Clinical Pharmacology (IUPHAR), the German Society for Experimental and Clinical Pharmacology and Toxicology (DGPT), the Arbeitsgemeinschaft für Angewandte Humanpharmakologie (AGAH), the American Society for Clinical Pharmacology and Therapeutics (ASCPT), the PharmaTrain Federation, and the PharmaTrain Certification Board. He is co-chair of the IFAPP-PharmaTrain “Medicines Development and Regulation: Working Group on Education in Low and Middle Income Countries”. He was chair of the Finance Committee of the 17th World Conference of Basic and Clinical Pharmacology (WCP2014) held in Cape Town.

His work is presented in 102 original publications, 17 book chapters, 64 invited lectures/chairmanships, and 126 conference presentations. He is Associate Editor of Frontiers in Pharmaceutical Medicine and Outcomes Research and of the Journal of Medicines Development Sciences.

Bernd Rosenkranz is board member of the Manenberg Aftercare Centre, Manenberg, Cape Town.

Harry Selker

Boston / US

Clinical Pharmacology

Harry P. Selker, MD, MSPH

Harry P. Selker, MD, MSPH is Dean of Tufts Clinical and Translational Science Institute (CTSI) (www.tuftsctsi.org) at Tufts University, and Executive Director of the Institute for Clinical Research and Health Policy Studies (www.icrhps.org) at Tufts Medical Center.  As Dean of Tufts CTSI, he provides leadership and is responsible for the programs and infrastructure that support clinical and translational research at the Tufts University Schools and affiliated hospitals, and other academic, community-based, and industry CTSI partners. He practices medicine at Tufts Medical Center.

Dr. Selker‘s research focuses on the development of treatment strategies, decision aids, and systems aimed at improving medical care.  He is known for a series of studies of the factors influencing emergency cardiac care and for development of “clinical predictive instruments,” mathematical models that are used as decision aids.  They provide emergency physicians and paramedics with predictions for their patients’ likely cardiac diagnoses and outcomes for real-time use in clinical care.  This has included conduct of multiple large national clinical effectiveness trials that have demonstrated better treatment and clinical outcomes for patients with acute coronary syndromes. Additionally, Dr. Selker has done research to advance clinical study design, execution, issues around informed consent, data analysis, mathematical predictive modeling of medical outcomes, and comparative effectiveness research.

Dr. Selker also has contributed to health services and health policy research, with a focus on translational research that ultimately has impact on the public’s health.  He has advised policymakers around healthcare delivery and medical research, including the House and Senate authors of the Affordable Care Act.  Nationally, Dr. Selker has served as president of the Society of General Internal Medicine, of the Society for Clinical and Translational Science, and of the Association for Clinical Research Training, and serves on boards of organizations and Federal agencies.  He is currently President of the Association for Clinical and Translational Science and Chairman of the Clinical Research Forum.

Michael Wolzt

Vienna / AT

Clinical Pharmacology

Martin Robinson

Harrow/ GBHarrow/GB

Clinical trial project management

Hubert Pehamberger

Vienna / AT

Dermatology

Univ.-Prof. Dr. Hubert Pehamberger

Geboren in Wien, verheiratet, 1 Sohn

Ausbildung:

1969 – 1975  Studium der Medizin in Wien, Promotion

1975 – 1981  Dermatologische Facharztausbildung an der I.Universitäts-Hautklinik Wien

1985             Habilitation – Das Maligne Melanom der Haut

1997             Berufung zum Universitätsprofessor für Dermatologie und Venerologie

Auslandsaufenthalte:

National Cancer Institute (NIH) Bethesda, Maryland

Harvard Medical School, MGH, Boston

Bisherige Funktionen:

• Vorstand der Universitätsklinik für Dermatologie der Medizinischen Universität Wien
• Leiter der Klinischen Abteilung für Allgemeine Dermatologie der Universitätsklinik Dermatologie in Wien
• Leiter des Ludwig Boltzmann Instituts für Klinisch Experimentelle Onkologie

Wissenschaftliche Publikationen:

• 280 wissenschaftliche Publikationen in Peer-reviewed Journalen – zitiert als „pehamberger h“ in pubmed.com (cumulativer Impact-Faktor >1.200)
• Zahlreiche Buchbeiträge
• Mehr als 200 eingeladene Vorträge bei internationalen Kongressen

Lehre:

• Lehrauftrag als Klinikvorstand
• 32 Dissertationen und Diplomarbeiten
• Ausbildungsverantwortlicher für die Facharztausbildung
• Lehrtätigkeit an der Schwesternschule des Allgemeinen Krankenhauses der Stadt Wien und Schwesternschule der Barmherzigen Brüder

Öffentlichkeitsarbeit – Prävention von Hautkrebs:

Melanom-Hautkrebs-Aufklärungskampagnen “SONNE OHNE REUE”

jährlich seit 1988 bis dato

Funktionen in akademischer Selbstverwaltung an der Medizinischen Universität Wien:

• Mitglied des Gründungskonvents und des akademischen Senats (4 Perioden) der Medizinischen Universität Wien und Sprecher der ProfessorInnen-Kurie (bis dato)
• Leiter des Teilprojekts 2 –Zentrumsbildung des Projekts UNIMED 2020 der Medizinischen Universität Wien und der Teilunternehmung AKH (2013-2015)
• Mitglied des Fakultätskollegiums und von Personal-, Struktur-, Betriebsführungs- und Klinikkommission der Medizinischen Fakultät sowie von zahlreichen Habilitations- und Berufungskommissionen (seit 1983)
• Mitglied des Kuratoriums (Aufsichtsrat) der Donau-Universität Krems (2 Perioden)

Funktionen in nationalen wissenschaftlichen Gremien:

• Österreichische Gesellschaft für Dermatologie und Venerologie (ÖGDV)

(Präsident 2007/2008 – permanentes Vorstandsmitglied)

• Arbeitsgemeinschaft Melanom und dermatologische Onkologie der ÖGDV (Vorsitzender)
• Österreichische Krebsgesellschaft – Österreichische Krebshilfe (Ausschussmitglied)
• Verein zur Förderung von Wissenschaft und Forschung AKH (2x Präsident, Vizepräsident, Generalsekretär)
• Ärztliche Jury des Theodor Billroth-Preises (Mitglied) 1990-1997)
• Vorsitzender des Beratergremiums des Jubiläumsfonds der Österreichischen

Nationalbank (bis dato)

Funktionen in internationalen wissenschaftlichen Gremien:

• European Association of Dermato-Oncology (EADO) (Präsident 2000-2010, Board Member)
• WHO Melanoma Programme (Member)
• Malignant Melanoma Group of the EORTC (Member)
• Kommission zur Früherkennung und Prävention von Hautkrebs, Deutschland

(Mitglied und Vertreter Österreichs)

Organisation Nationaler und Internationaler Kongresse:

• 16^th World Congress on Cancers of the Skin, Wien, 30.8. bis 3.9.2016 – in Vorbereitung
• 7^th World Congress on Melanoma, Wien, 2009
• Jahrestagung der Österreichischen Gesellschaft für Dermatologie und Venerologie, Wien, 2007 und 2008
• 10th World Congress on Cancers of the Skin, Wien, 2005
• Meeting of the European Association of Dermato-Oncology (EADO), Wien, 2001

Andreas Steiner

Vienna / AT

Dermatology

Univ. Prof. Dr. Andreas Steiner

EDUCATION AND CAREER

May 30^th, 1973           High school graduation

• Medical School, University of Innsbruck, Austria

1. D. graduation: March 26^th, 1980

• Internship, Hospital Gmunden, Austria

1983-1989                  Residency training in Dermatology, Department of Dermatology I., University of Vienna, Medical School

Nov. 27^th, 1987           Medical specialist for Dermatology and Venerology

Dec. 5^th, 1994             Assistant Professor for Dermatology and Venerology (“venia legendi”)

Dec. 15^th. 1995           Clinical investigator (GCP-training and exam)

Many clinical studies designed and performed

July 1^st, 1998               Associate Professor for Dermatology and Venerology, University of Vienna

Since 2008                  Head of the Department of Dermatology, Krankenhaus Hietzing, Vienna

Univ.-Prof. Dr. Andreas Festa

Vienna / AT

Diabetology, Management Board,

Univ. Prof. Dr. Andreas Festa

Dr Festa has been active in research/development and clinical care for patients with diabetes now more than 25 years, focusing on the management of type 1 and type 2 diabetes, as well as the interplay between cardiovascular risk factors, CV risk and the pathophysiology of type 2 diabetes. He has received numerous research awards from national and international associations, has been an active reviewer for top peer-reviewed journals (to date more than 150 reviews for Diabetes Care), and a member of the Diabetes Care Editorial Board (2007-2009). Dr Festa has published more than 55 articles in top-listed journals, including The Lancet, Circulation, Diabetes Care, JCEM, Am J Cardiol, ATVB, Diabetologia, and Diabetes.

Dr Festa received his medical degree from the University of Vienna, where he was also appointed Professor of Medicine in 2012. His academic career included a research fellowship at the Dept. of Clinical Epidemiology in San Antonio, Tx, USA, before he joined the pharmaceutical industry, where he held various positions in innovative companies covering clinical research and development as well as senior global management.

Currently, Dr Festa is head of an outpatient clinic for patients with diabetes and metabolic diseases at LK Stockerau Hospital, Nö, Austria. In addition, he holds various teaching appointments, is actively involved in post-graduate medical education and works as an independent consultant in the field of health care for people with diabetes and associated conditions.

Bernhard Ludvik

Vienna / AT

Diabetology

Prim.Univ.-Prof.Dr. Bernhard Ludvik

CURRENT POSITION AND FUNCTIONS

Head/Department of Medicine 1 (Endocrinology/Diabetes/ Nephrology), Rudolfstiftung Hospital

Associate Professor of Medicine, Medical University of Vienna, Austria

Member of the Editorial Board of Obesity Facts-The European Journal of Obesity

Member of the Editorial Board of Hamdan Medical Journal

 Past President Austrian Obesity Association

President of the Diabetes Initiative Austria

Past-President of the Austrian Diabetes Association

Member of the Scientific Committee of the IFSO (International Federation for the Surgery of Obesity)

Member of the Local Organisation Committee of the 50^th EASD (European Association for the Study of Diabetes) 2014 in Vienna

SCIENTIFIC INTEREST

Research in obesity, metabolic syndrome and diabetes, more than 130 peer-reviewed publications in high ranked journals, reviewer in top journals, successful application for research grants, organisation of national and international meetings

RESEARCH HIGHLIGHTS

Basic research on the pathogenesis and therapy of type 2 diabetes, the metabolic syndrome and obesity

Clinical research on the treatment of obesity, diabetes and lipid metabolism as the principal investigator of numerous studies and clinical trials in phases 1, 2 and 3

Nutritional Medicine

Original publications (Medline: 147) in many top journals, review articles, book contributions, numerous presentations at national and international congresses, organization of national and international congresses, reviews for top journals (e.g. Diabetes, Diabetes Care, Diabetologia, European J. Clin. Investigation)

Prim. Univ.-Prof. Dr. Ludwig Kramer

Vienna / AT

Gastroenterology

Citizenship:                                  Austria

Medical education:                  1984-1992 Vienna University Medical School; 1990/91 Research Fellow,       1^st Medical Clinic, University Vienna, with Prof K. Lenz, Prof G. Grimm.

Postgraduate Education       1992-1998: Specialist training in Internal Medicine, Department of Medicine IV (Head: Prof A.Gangl)

                                                           1996: Research Associate with Prof Roger Williams CBE, Institute of Liver Studies, King’s College Hospital, London, UK.

2001: Specialist degree for Medical and General Intensive Care Medicine

2002: Radiology training (sonography, computed tomography).

2003/5: in-depth training and Specialist degree in Gastroenterology (endoscopy, clinical hepatology, gastroenterology)

2004- 2007: INTERREG diplomate for clinical research and EBM, Vienna School of Clinical research

Invitations: Invited lecturer at national and international scientific meetings organized by the European Association for the Study of Liver diseases (EASL), European Society of Nephrology, Dialysis and Transplantation (EDTA), National Institute of Health (Bethesda, USA), European Society for Artificial Organs (ESAO), European Society of Intensive Care Medicine, Eur Academy Ansthesiol., Societa italiana di anestesia analgesia rianimazione e terapia intensiva, ISFA, Fortis Health Care India, etc.

Peer reviewer (selection): Gastroenterology, Hepatology, J Hepatology, Intensive Care Medicine, Critical Care Medicine, Liver International, Nephrol Dial Transplant, Am J Med., Am J Nephrol., Eur J Clin Invest, Eur J Ultrasound, Wiener Klin Wochenschrift, Clin Neurophysiol, Therapeutic Apheresis and Dialysis, diabetologia, Diabetes Care, J Hum hypertension, PLOS ONE, Therapeutics and Clinical Risk Management; Hepatic Medicine: Evidence and Research, Journal of Gastroenterology and Hepatology.,

Awards:                                        12/1999 Theodor-Billroth Prize (1.) Ärztekammer Wien

10/2000 Paracelsus Award, Austrian Society for Internal Medicine.

12/2011: Health Prize, City of Vienna

Academic positions:                2002: Lecturer in Internal Medicine, University of Vienna

2005-2007: Program coordinator for Internal Medicine, Bernhard Gottlieb Zahnklinik, Vienna

2006-2007 Voting Member, Study Commission, Medical University Vienna

Other activities:                        2010-2013: Delegate for Vienna Health Goals, City of Vienna

                                                           2010-2013: Member of the Task Force Obesity, City of Vienna

2009-current: Referent for professional policies, Austrian Society for Gastroenterology & Hepatology

March 2013: National Delegate, European Board of Gastroenterology & Hepatology (EBGH)

January 2014: Chair, CME committee, EBGH

2015: elected representative of Hietzing physicians

Current clinical position:      March 1, 2008: Head, 1^st Dept with Gastroenterology, Krankenhaus Hietzing, Vienna.

Clinical trial experience:       1998-2015 Principal Investigator of academic studies in Hepatology, Intensive Care Medicine and General Internal Medicine, and of phase 2-4 studies involving patients with liver disease, viral infection, bleeding and coagulation disorders, inflammatory bowel disease and extracorporeal detoxification in liver disease.

Paul Sevelda

Vienna / AT

Gynecology

After graduating from high school in 1973, Paul Sevelda studied medicine at the University of Vienna, where he received his doctorate in 1979. He then completed training as a general practitioner at the Hanusch Hospital, and in 1983 he received his decree as a general practitioner. He then stayed as a specialist in gynecology and obstetrics at the 1st University Women’s Clinic in Vienna, where he became senior physician in 1987. In 1991 he became a university lecturer in gynecology and obstetrics at the medical faculty of the University of Vienna (since 2004 Medical University of Vienna), where he was appointed professor in 1995. In 1997 he became Head (Primarius) of the Department of Gynecology and Obstetrics at the Lainz Hospital (later the Hietzing Hospital). Since 2000 he has also served as President of the Austrian Cancer Aid. In 2006, the Karl Landsteiner Institute for Gynecological Oncology and Senology was founded, headed by Paul Sevelda. He has also been a member of the Supreme Health Council since 2008. In his scientific and clinical work, he deals, among other things, with the surgical and drug treatment of breast cancer and gynecological cancer, early cancer detection, check-ups and cancer prevention as well as vaccination against HPV infections. Paul Sevalda’s specialties also include breast-conserving therapies for breast cancer and laparoscopic surgery.

At the beginning of February 2018, in his capacity as President of the Austrian Cancer Aid, together with the President of the Medical Association Thomas Szekeres, he submitted the “Don’t smoke” referendum for a smoking ban in gastronomy to the Federal Ministry of the Interior.

Petra Acher

Germany / DE

Health Economy and Health Technology Assessment (HTA)

Networker in health care politics as general manager Frankfurter Forum e.V.

Petra Acher graduated from the German Justus Liebig University, Giessen in agriculture with specialisation in animal production specialising in economics and animal health.

She began her career with Elanco, an animal health division of Eli Lilly & Co, working in market research, marketing and key account management, before she changed to the pharmaceutical department within Lilly Germany.  In various sales leadership assignments, she was responsible for market introduction of products in diabetes, CNS, cardiology, osteology and others. In this time she developed outstanding leadership and coaching skills specially in difficult people situations.

In 2007 she changed to corporate affairs becoming responsible to build and develop a new group of pharma key account management for the hospital business and later including contract business with sickness funds and other health care stakeholders. As director of key account management market access, she developed various successful market access strategies, becoming an expert and advisor within Lilly for various European and non-European countries (including China &Australia).

Since 2022 she is general manager of a non-profit organization, which answers principal questions on socio- and health politics.

Petra Acher is married and has 3 children.

Ernst Agneter, MD, PhD, MBA

Vienna / AT

Health Economy and Health Technology Assessment (HTA)

Head of Center for Pharmacological Medicine, Sigmund Freud Medical University Vienna

Managing Director, Agneter PharmaConsulting GmbH, Chairman of the Pharmig working group Health Economics & Reimbursement of Executive Board of Pharmig, Association of the Austrian Pharmaceutical Industry

Ernst Agneter is a specialist in pharmacology and toxicology. After receiving his PhD in 1989, he worked as a doctor of general medicine for the Ministry of Health in the area of drug approvals and as assistant at the Pharmacological Institute of the University of Vienna. In 2000, he obtained the teaching license for pharmacology and toxicology. In 2018 he was appointed to the Chair of Pharmacology of the Sigmund Freud Private University in Vienna. In addition, he holds a Master of Advanced Studies, a Master of Business Administration and an Examination in Wholesale Medicines and Poisons. Agneter served as Medical and Marketing Director in an international pharmaceutical company, as well as an external expert of the Federal Ministry for Social Security and Generations, and as a member of the EMEA experts nominated by Austria, as well as peer reviewers. In 2001, he founded the Agneter PharmaConsulting GmbH with a focus on the preparation of preclinical and clinical expert reports, evaluation of pharmaceuticals as well as pricing and reimbursement of proprietary medicinal products.

Lieven Annemans

Ghent / BEL

Health Economy and Health Technology Assessment (HTA)

Lieven Annemans is a Senior Professor of Health Economics at the Faculty of Medicine at Ghent University, Belgium. He has 20 years of experience in international health economics research. For many years he is a well sought expert consultant and lecturer in health technology assessment (HTA). He was advisor to the Belgian Minister of Health from 2001 to 2003 and president of the Flemish health council from 2003 to 2009. He is Past-President of ISPOR (International Society of PharmacoEconomics and Outcomes Research). He published more than 250 papers and several books on health economics and HTA.

Anna Bucsics MD

Vienna / AT

Health Economy and Health Technology Assessment (HTA)

Former department Head, Department of pharmaceutical Affairs, Federation of Austrian Social Insurance Institutions

MoCA Project Advisor since 2016. Lecturer at the Vienna School of clinical Research. Expert panel member of the Austrian Federal Administrative Court Member of the European Commission Experts Group on Rare Diseases. External Lecturer at the Department of Finance, University of Vienna

Advisor to the MEDEV Committee (an informal group of representatives and experts from payer institutions in Europe), Participation in European projects such as EUnetHTA, the High Level Pharmaceutical Forum, the Platform on Access to Medicines in Europe (in the working groups on access to biosimilars and orphan medicinal products), and Parallel Scientific Advice at EMA.

Department Head for the Main Association of Austrian Social Insurance Institutions (MAASSI) until the end of 2013. Previously, auditor for pharmaceutical expenditures at the Viennese Social Health Insurance and as pharmacological consultant for MAASSI

Training in internal medicine in Graz, diploma as a specialist for Pharmacology and Toxicology.

Medical degree from the Karl-Franzens-University of Graz, Austria, postgraduate research work in neuropharmacology at the Department of Experimental and Clinical Pharmacology.

Dávid Dankó

Hungary

Health Economy and Health Technology Assessment (HTA)

Dávid Dankó, PhD, MSc, is managing partner of Ideas & Solutions. He graduated in economics from Corvinus University of Budapest after scholarships in Sweden and Germany. He earned his PhD degree in 2012 with a thesis on long-term resource management in the pharmaceutical industry. Before 2010, he worked as Deputy Director of Reimbursement at the Hungarian National Health Insurance Fund. He has lectured at Vienna School of Clinical Research, Université Lyon 1 (EMAUD), Semmelweis University of Budapest, Eötvös Loránd University, and speaks regularly at international workshops and conferences on pharmaceutical and medical device reimbursement. He is also a regular invitee to international advisory boards and policy roundtables. Dávid works in English, German, Italian and Russian.

Prof. Dr. med. Dominique Dubois

Brussels / BE

Health Economy and Health Technology Assessment (HTA)

Dominique Dubois MD FBCPM FFPM

Physician Specialist in Pharmaceutical Medicine. Lecturer in Pharmacoeconomics & Patient Reported Outcomes Research. Vice-Chairman PHARMED PharmaTrain Centre of Excellence. Author of >50 publications in peer-reviewed journals. Specialty Chief Editor of Frontiers in Pharmaceutical Medicine and Outcomes Research.

Dominique contributed to the FDA PRO draft guidance, the EMEA reflection paper on HRQL measures, and an expert guidance report on coverage decision-making in orphan diseases. He was also largely instrumental in achieving a successful NICE Single Technology Appraisal.

Sebastian Iovan

Italy / IT

Health Economy and Health Technology Assessment (HTA)

Associate Vice President, Eli Lilly

Pricing, Reimbursement, Market Access Italy, CEE, Israel, Russia

Sebastian is a Medical Doctor with a Master of Science in Health Economics from Bocconi University Milan, Italy and an MBA from IE Business School Madrid, Spain. In his 15 years with Eli Lilly, Sebastian has been responsible for Pricing & Market Access in different regions around the world. He also led Global Market Access Group for Lilly Diabetes portfolio based out of Indianapolis.

In his recent role, he is leading Pricing, Reimbursement & Market Access for Italy, Central Eastern Europe, Israel & Russia based in Florence, Italy.

Jürgen Raths

Geneva / CH

Health Economy and Health Technology Assessment (HTA)

Dr. Raths studied medicine and dentistry at the Universities of Heidelberg, Bonn and Cologne. He obtained his Doctorate in Medicine at the University of Bonn. He is MD with 30 years of experience in the European and global pharma business, with positions held in clinical research, medical, marketing, sales and General Management in Europe and the USA. Jürgen served as CEO in assignments in public and private specialty pharma companies. Jürgen is Managing Director of Cordée Consulting in Geneva and supports innoplexus, a German-Indian Big Data and Artificial Intelligence company as Head of Life Sciences. He has leadership experience in: general management, company creation, M&A, change management and corporate restructuring situations, as well as in global business development.

MD Jörg Rustige, MD

Germany

Health Economy and Health Technology Assessment (HTA)

Jörg studied physics in Kiel and Hamburg, and worked several years as a physicist in the field of high energy particles. He also completed Medical School in Hamburg, and has been practising fo more than 15 years in university and academic teaching hospitals specializing in internal medicine, interventional cardiology, emergency medicine and intensive care. He participated in the design and conduct of clinical trials, and initiated one of the biggest real-life registries in myocardial infarction in Germany. Jörg has also decades of experience in the pharma industry in Europe and North America, being responsible at different stages in senior positions for medical affairs, medical information, clinical research in all phases, regulatory, quality assurance and basic research laboratories. Lately, he had supported European small pharma companies in Medical Affairs and Regulatory and he is now active with Cordée Consulting and VSCR.

MD Steffen Wahler, MD

Germany / DE

Health Economy and Health Technology Assessment (HTA)

Steffen is Managing Director of Hamburg-based St. Bernward Consulting. He has held leadership positions in German health insurance as well as in medical device and pharmaceutical industry. He served as director in the German pharma trade association and was in the curator-board of IQWiG and the HTA division of DIMDI, both German health care evaluation bodies. Steffen obtained his Doctorate in Medicine at the University of Rostock and specialized as Diabetologist. He earned degrees in economics at Universities of California and York/England as well as at INSEAD, France. He is regularly publishing in his and adjacent fields, like epidemiology and care organization research. He co-authored the German Health Economics guidelines (Hanover Consensus). In his 25 years in local and global health care.

Claudia Wild

Vienna / AT

Health Economy and Health Technology Assessment (HTA)

Director, Strategy and management
Head: Evaluation of medical procedures, European cooperation

Claudia Wild is Chief Executive Officer (CEO) of AIHTA GesmbH since 2020. Before she has been Director of the LBI-HTA since its establishment in 2006. From 1989-2006 she worked as a Senior Researcher at the Institute of Technology Assessment at the Austrian Academy of Sciences and helped developing the research field Health Technology Assessment in Austria. Prior to that, she was Research Associate on “media impact on cognitions” at the Institute for Communications and Political Science at the University of Nuernberg/Germany and worked as a freelancer on media impact research projects. She studied communications & psychology at the University of Vienna and political sciences at the Ohio University in Athens/Ohio/USA and completed her studies with a Graduation at the University of Vienna as Doctor of Philosophy in 1985. In 2009, she habilitated in social medicine (Medical University Graz) on the topic of “resource allocation in health-care systems”.

Andras Fehervary

Geneva / CH

Health Policy and Management

Andras Fehervary is an advocacy, market access and public affairs strategist with 25 years’ operational and leadership experience in life sciences, who contributed to more than 20 drug launches and designed market shaping and policy advocacy campaigns around key innovation and access priorities.

Andras most recently served as Corporate Vice President and Global Head Public & Government Affairs for Boehringer-Ingelheim. He previously held senior functional leadership positions with Amgen, Novartis with Eli Lilly & Co.   Andras advised the European People’s Party (EPP) group of European Parliament on healthcare issues. He was a member of the EU Committee of Experts on Rare Diseases (EUCERD) where he contributed to the EU’s rare disease policy. He was a founder of Rare Cancers Europe. He is since 2007 an active member of the Ad Hoc Council (The European Business Government Relations Council). He has authored a number of publications in health, human rights and services and is a frequent moderator and speaker.

Andras holds an MBA from INSEAD; a MA in international law from the Geneva Graduate Institute (IUHED); and a M.A.L.D. from the Fletcher School of Law & Diplomacy, a BA and Graduate Diploma were from Johns Hopkins University and JHU SAIS Europe. He is currently pursuing a Ph.D. in health policy at Semmelweis University in Budapest.

Andras speaks native English, fluent Italian and Hungarian, and proficient German and French. He is married with two children, and based in Basel, Switzerland.

Manfred Dierich

Innsbruck / AT

Microbiology

O. Univ.-Prof. Manfred P. Dierich

O. Univ.-Prof. Manfred P. Dierich studied medicine in Cologne, Vienna, Graz and Ottawa 1961-1966. Approval as Dr.med. 1968.

1970 Start of training in Medical Microbiology and Immunology in Mainz (1973-1975 Scripps Clinic and Research Foundation, La Jolla, California); 1977 Habilitation in Medical Microbiology; 1979 Professor of Medical Microbiology in Mainz.

1983 Full Professor of Hygiene at the University of Innsbruck and chairman of the Institute of Hygiene until the end of 2009.

He held various positions such as speaker of the professors of the medical faculty , vicerector and rector of the Medical University of Innsbruck and chairman of several commities in the university and in science politics. His science centered around “Host parasite relationship “, specifically complement and macrophages of special importance was his AIDS Research. He published several hundred scientific papers.

Heinz Ludwig

Vienna / AT

Oncology

Oncologist, Wilheminenspital, Vienna

Heinz Ludwig, MD, is Professor of Internal Medicine and Haemato-Oncology and chairs the Wilhelminen Cancer Research Institute at the Department of Medicine I, Centre for Oncology and Haematology, Wilhelminenspital, Vienna, Austria. Areas of specific research and interests: Professor Ludwig’s research interests span the field of therapeutics in haematology and medical oncology. His research focuses on the biological and clinical aspects of multiple myeloma (MM), as well as on the analysis of factors associated with anaemia and the treatment of anaemia in cancer patients.

In the early days of his research activities, he was able to show a significant activity of erythropoietin in treating anemia in myeloma (NEJM 1990). Professor Ludwig serves as peer reviewer of several international journals and has published a large number of scientific articles. He is a strong supporter of patient’s interests and patient’s rights.

Michael Micksche

Vienna / AT

Oncology

Gerald Prager

Vienna / AT

Oncology

DDr. Wolfgang Wein

Vienna / AT

Oncology

Former General Manager Merck Austria

Wolfgang Wein, former Managing Director of Merck Austria, has more than 25 years of pharmaceutical

experience. After studying medicine and philosophy and receiving post-graduate training at the Vienna University of Economics and Business Administration, he gained experience in various areas of the pharmaceutical industry as well as in countries such as England, Japan and Germany.

From 2005, as Executive Vice President Oncology, he led Merck‘s global oncology business in Darmstadt. From 2005–2011 he was a member of the Executive Board of Merck-Pharma. Since 2013 he has headed the Western Europe region.

Christoph Zielinski

Vienna / AT

Oncology

Prof. Christoph C. Zielinski, M.D.

Professor Zielinski is Director of the Clinical Division of Oncology and Chairman of the Department of Medicine I at Medical University Vienna, Austria. He also serves as Director of the Comprehensive Cancer Center at Medical University Vienna and the General Hospital in Vienna, Austria, and is President of the Central European Cooperative Oncology Group.

Professor Zielinski completed his medical training at the University Hospital Vienna and began his career with a position as a research fellow at the Cancer Research Center at Tufts University, Boston, USA. His recent clinical research activities cover a wide range of cancer therapies, with particular focus on clinical trials, breast and lung cancer research and treatment and development of targeted drugs. He has published env. 530 original papers and reviews in peer-review journals and many books including the “State of Oncology 2013” published together with Peter Boyle et al. by IPRI.

Prof. Zielinski is Editor in Chief of the Open-Access Internet Journal “ESMO Open – Cancer Horizons”.

In 2013, Professor Zielinski received a “Dr. h.c.” degree from Titu Maiorescu University in Bucharest.

Professor Zielinski is a member of the European Society for Medical Oncology (ESMO) where he serves in the Executive Board and as Chair of the Fellowships and Awards Committee. He was Local Officer of the ESMO Annual Meeting 2012 and the ECC Meeting 2015. Prof. Zielinski is also member of he American Society of Clinical Oncology (ASCO) and the American Association for Cancer Research (AACR).

Prim. Dr. med. Michael Amon

Vienna / AT

Ophthalmology

Dr. Susanne Binder

Vienna / ATWien / AT

Ophthalmology

Dr. Susanne Binder, MD is born in Vienna and had her medical training at the medical University in Vienna.  She received a sub-specialized training in vitreoretinal surgery and research in 1979/80 at the Johns Hopkins University in Maryland and the Duke Eye Center in Durham, both USA.

She is Professor of Ophthalmology since 1988.  In 2017 she was appointed Professor of Special Ophthalmology  at the Sigmund Freud University in Vienna.

Until 2015 she was chairman at the Department of Ophthalmology at the Rudolf Foundation Clinic in Vienna, a teaching hospital of the Medical University Vienna and was leading the Eye Center Project of the Wiener Krankenanstaltenverbund(KAV) in Vienna until 2017.  In addition, she chaired a research institute, the Ludwig Boltzmann Institute for Retinology and Biomicroscopic Lasersurgery between1997 and 2015. Today her scientific work is continued at the Karl Landsteiner Institute for Imaging and Retinal Research at the Rudolf Foundation in Vienna and the Sigmund Freud University.  She was vice-chairman of the University Eye-Clinic Vienna since 1990 before she received the chair( Primariat) at Rudolf Foundation Clinic in 1995.

Her sub – speciality is vitreo-retinal diseases and microsurgery, research in age related macular degeneration (AMD), retinal regeneration treatments like retinal cell transplantation and retinal implants and imaging. In optical coherence tomography (OCT) she has developed a new OCT -integrated microscope together with Carl Zeiss Meditec/Oberkochen.

After her medical training in Vienna in Ophthalmology she spent time in Johns Hopkins University and Duke University for further research in retinal diseases and vitreous surgery.

Dr. Binder has published more than 380 original peer reviewed articles in both English and German. She was Editor in Chief of the Austrian Ophthalmic Journal, the “Spektrum für Augenheilkunde”. In adition she was editor on 4 books and has written many book articles. Dr. Binder is a member of many ophthalmic societies including the American Academy of Ophthalmology, the Association for Research in Vision and Ophthalmology (ARVO), the Retina Society, the Macula Society, the Club Jules Gonin, the Association of Retina Specialists and also the Austrian and Vienniese Ophthalmic Society.

She was President of the Austrian Ophthalmic Society between 2004 and 2009 and secretary of the Austrian Ophthalmic Society between 2009 and 2011 and a member of the Medical Counsel for the Minister of Health in Austria and the Mayor of Vienna.

Since 2012 she is appointed as Adjunct Professor of Clinical Ophthalmology at Weill Cornell Medical College/New York.

Dr. Binder has trained many young ophthalmologist and organized surgical training weeks (Wet labs) for hands on training as well as several international conferences in Vienna.  She participated in the American Austrian Foundation project, the European Society of Ophthalmology and is a regularly invited lecturer and speaker at national and international meetings.

Susanne Binder MD
Univ. Professor
Sigmund Freud University
1020 Vienna
Freudplatz 1

or

Office
Susanne Binder MD
Zeltgasse 1/9
Tel: 0043 1 405 64 02
FAX: 0043 1 405 64 02
mailto: susanne@susannebinder.com

Alexander Hönel

Vienna / ATWien / AT

Pharmaceutical Medicine

Mag. Dr. Dr. Prof. h.c. Alexander Hönel holds a degree in law and a degree in politics/history from the University of Vienna, a degree in veterinary medicine, Vienna, a Master in Public Health (MBA), Master of Laws (LL.M.) in Medical Law and a MSc in Pharma Management. He is university lecturer at several universities in Austria, Germany and Italy, and established a seminar company for GxP in 2019. Mainly he is doing audits worldwide, special field of interest is clinical development.

He spent 8 years in industry, as Medical Manager  at Hoechst/Hoechst Marion Roussel and Schering in Austria, has built up the Austrian Federal Inspectorate and headed it from 2004 till 2014, is head of one of the major Ethics Committees in Austria, and acts as legal consultant in GxP.

He is member of various international organizations, not only in GCP and GMP and Medical Devices, also in the board of the International Rescue Dog Association and active Member of the Red Cross.

His work is presented in dozen publications, covering a broad field from Pharma, to law up to history.

Dr. Alexander Hönel is board member of the NADA (Austrian Anti Doping Agency), was member of the management board of PIC/S (Pharmaceutical Inspection Cooperation Scheme), and EMA (European Medicines Agency) expert for GCP and Pharmacovigilance, member of EF-GCP, ClinOps-Circle Austria, and DGPharMed.

Ingrid Klingmann

Brussels / BE

Pharmaceutical Medicine

Ingrid Klingmann, MD, PhD, FFPM, FBCPM
European Forum for Good Clinical Practice (EFGCP), PHARMAPLEX bvba

Physician, specialized in General Medicine, Clinical Pharmacology and Pharmaceutical Medicine with over 30 years of experience in different senior operational and managerial functions in pharmaceutical companies, CROs and academic sites, focussing on clinical trial management, ethical and regulatory aspects.
Since January 2003 she has her own pharmaceutical development and site management support consulting company.
Dr. Klingmann is Chairman of the Board of the European Forum for Good Clinical Practice (EFGCP). On behalf of EFGCP she was and is involved in different FP7- and IMI-funded projects (ICREL, PatientPartner, PharmaTrain, EUPATI, Combacte-Magnet) and with her company in the FP7-funded paediatric LENA project and the IMI-project SPRINTT. Currently Dr. Klingmann is also President of PharmaTrain Federation.
Dr. Klingmann is Module Chair in the post-graduate Master Course in Regulatory Affairs at the University of Bonn, Germany, and is lecturer in the Diploma Course in Clinical Trial Practices and in the ECPM course at University of Basel and in the Pharmed course at Université Libre de Bruxelles, Belgium.

Bernd Minnich

SalzburgSalzburg / AT

Pharmaceutical Medicine

Ao. Univ.-Prof. Mag. Dr. Bernd Minnich, FRMS holds a degree in neurobiology and a degree in zoology and electron microscopy from the University of Salzburg. He is university professor at the Paris Lodron University of Salzburg / Dept. Biosciences (PLUS) and the Paracelsus Medical University (PMU) in Austria since 2003. His research interest focuses on vascular biology in animal experiments and applied human studies. Besides lecturing anatomy and physiology, he teaches biostatistics for more than 25 years in biology and medical classes. He is also coordinating courses on biostatistics and epidemiology for human medicine at the PMU.

After his habilitation in electron microscopy and vascular biology, he became head of several divisions at the University of Salzburg. Since 2008, he is member and reviewer of one of the major Ethics Committees in Austria and in 2020, he became vice head of the Ethics Committee of the federal state of Salzburg.

He is board member of the Austrian Society of Electron Microscopy (ASEM) and member of various international scientific organizations. In 2014, he was awarded the fellowship of the Royal Microscopy Society, Oxford, GB (FRMS).

His scientific work presented in more than 150 publications covers a broad field from developmental biology, vascular biology, NETosis research to clinical studies in cardio-vascular surgery.

Dr. Bernd Minnich was involved in various clinical studies in different fields of medical research by setting up study designs and performing biometry and statistical analysis.

Peter Stonier

London / GB

Pharmaceutical Medicine

Prof. Peter Stonier

MB ChB BA BSc PhD MRCPsych FRCP FRCPE FFPM

Peter Stonier is a pharmaceutical physician with over 35 years of experience in medicines development, clinical research, life-cycle management & drug safety / pharmacovigilance. He was medical adviser, medical director & board member of the Hoechst Marion Roussel group of companies, UK (now Sanofi) between 1977 & 2000, & group medical director and QPPV of Amdipharm plc 2004-2013. He is currently an independent pharmaceutical physician and consultant in pharmaceutical medicine.

He is Director of Education & Training at the Faculty of Pharmaceutical Medicine & national Programme Director for pharmaceutical medicine specialty training (PMST). He is Board Member of the PharmaTrain Federation, developing & introducing internationally a platform of education & training for all in medicines development / clinical research: industry, academia, clinical practice (clinical trial investigators).

Peter was a founding Fellow of the Faculty of Pharmaceutical Medicine, Royal Colleges of Physicians UK (1989) & made a major contribution to achieving recognition & legal listing for the medical Specialty of Pharmaceutical Medicine in 2002.

He is visiting Professor in Pharmaceutical Medicine at Kings College London, Institute of Pharmaceutical Sciences. Whilst visiting professor at University of Surrey, the first Masters programme (MSc) in Pharmaceutical Medicine was introduced under his co-direction.

He is past President of the Faculty of Pharmaceutical Medicine (FPM), Royal Colleges of Physicians, UK, past President of the International Federation of Associations of Pharmaceutical Physicians and Pharmaceutical Medicine (IFAPP), past Chair of the British Association of Pharmaceutical Physicians (BrAPP) and past President of the Royal Society of Medicine’s Section for Pharmaceutical Medicine & Research.

Peter Stonier graduated in physiology (BSc 1^st Class Hons) with a PhD in protein chemistry (inborn errors of metabolism), Universities of Birmingham & Sheffield, UK, 1969. He studied medicine at the Manchester Medical School, qualifying MBChB with honours in 1974.

His publications include texts in pharmaceutical medicine & edited works in human psychopharmacology, clinical research & paediatric clinical research, medical affairs & careers in pharmaceutical medicine.

M.D., D.Sc. Sandor Kerpel-Fronius

Budapest / HU

Pharmacology

Sandor Kerpel-Fronius, M.D., D.Sc.

Dr. Kerpel-Fronius was born in Budapest, Hungary, November 4, 1940. He obtained medical diploma at the Semmelweis University in 1964. At the same university he received board certificates in Clinical Laboratory Sciences and Clinical Pharmacology in 1977 and 1980, respectively. From 1964 to 1975 he worked in neurobiology at the Semmelweis University. In 1967-68 he was a research fellow at the Karolinska Institute, Stockholm and 1972 to 1974 a Sloan Fellow at the Maryland Psychiatric Research Center in the US. From 1975 to 1989 he led a clinical pharmacologic research group at the National Institute of Oncology in Hungary. In 1988 he spent a sabbatical year at the Cancer Center of the Wayne State University, Detroit, US. 1989-2001 he worked in clinical drug development within the international pharmaceutical industry. In 2001 he became Professor of Clinical Pharmacology at the Department of Pharmacology and Pharmacotherapy of the Semmelweis University. He was the General Director of the Hungarian National Institute of Pharmacy (Hungarian Drug Regulatory Agency) in 2002. Presently he is retired but continues to teach clinical pharmacology as Senior Scientific Advisor. In addition, he participates as lecturer of medicines development at several international courses. Committee memberships: IFAPP Board of Officers, Head of the IFAPP Working Group on Ethics; Educational Subcommittee of the EACPT (finished 2015); Executive Board of the IMI-PharmaTrain; Member of the St Steven Academy of Sciences, Hungary. Chairman of the Natural Sciences Section, 2001).

Robert Mader

Vienna / AT

Pharmacology

Prof. Robert M. Mader, D. Sc.
Clinical Division of Oncology, Department of Medicine I
Comprehensive Cancer Center of the Medical University of Vienna
Austria

Examinations and degrees:
D.Sc. in Technical Chemistry (Dr.techn.rer.nat., 1986) and Diploma in Technical Chemistry (DipI.lng., 1983)

Appointments:
Director for Translational Research at the Department of Medicine I, Medical University of Vienna (from 2010) and Associate professor and Program Director for “Molecular Pharmacology” at the Comprehensive Cancer Center of the Medical University of Vienna

Activities as chair:
from 2010 Coordinator of the Research Cluster “Experimental Therapy and Drug Resistance” at the Comprehensive Cancer Center Wien
2013-2014 Coordinator of the Task Force „Extravasation” at the Comprehensive Cancer Center Vienna

Meinhard Kneussl

Vienna / AT

Pneumology

Wolfgang Pohl

Vienna / AT

Pneumology

Cyril Höschl

Praha / CZ

Psychiatry

Cyril Höschl, MD, DrSc, FRCPsych, received his MD grade at the Charles University in Prague in 1974. After completion of his residency he became a research fellow and psychiatrist at the Psychiatric Research Institute (PRI) in Prague and an assistant professor at Charles University in Prague. His research interests included psycho­neuroendocrinology, psychopharma­cology and biological psychiatry. In 1984, professor Höschl presented his original work on neuroendocrine tests in psy­chiat­ry at several Canadian universities. In 1985, he was invited to lecture at New York Uni­versity on his pioneering studies on calcium channel blockers in the treatment of affective disorders.

After the breakdown of communism, he was elected the Dean of the Third Medical Faculty of Charles University in Prague (1990-1997) and appointed profes­sor of psychiatry and a chair at Prague Psychiatric Centre. At present he is the Director of the National Institute of Mental Health at Klecany, Czech Republic. Since 2004 until 2011, he was also a professor of psychiatry at the University of P.J.Safarik in Kosice, Slovak Republic, and Vice-president, Vienna School of Clinical Research, Vienna, Austria. In Prague he coordinates research on neurobiology of schizophrenia and affective dis­or­ders.

In 2007-2008 Professor Höschl was the President of the European Psychiatric Association (EPA). From 2004 to 2010, he was the President of the Czech Medical Academy and from 2008 to 2009 the President of the Federation of European Academies of Medicine (FEAM, Brussels).

Professor Höschl was an author of a fundamental trans­for­mation of the medical curriculum at the 3rd Medical Faculty of Charles University in Prague. He is an honorary editor of Neuroendocrinology Letters, editor-in-chief of Psychiatrie (CZ) and member of the editorial board of International Journal of Psychiatry in Clinical Practice, among others.

Professor Höschl published more than 200 scientific publications, including 3 monographs, and co-edited 5 additional monographs and textbooks.

The complete CV is available on www.hoschl.cz.

Walter Hruby

Vienna / AT

Radiology

Univ. Prof. Walter Hruby, M.D.

Univ.-Prof. Dr. Walter Hruby, M.D., President of the College of Physicians in Vienna; Emeritus of Radiology Dept. at Vienna’s Danube Hospital. Chairman of the Ludwig Boltzmann-Institute for Digital Radiography & Interventional Radiology until 2016.

His main research focus is Digital & Interventional Radiology. He has given 350+ presentations, published 200+ papers, and edited books and many book chapters. Hruby is member of numerous scientific societies and has received various Honorary Memberships; he functions as a reviewer and co-editor of various medical journals.

Josef Smolen

Vienna / AT

Rheumatology

Michael Gnant

Vienna / AT

Surgery

Professor Michael Gnant, MD FACS FEBS

Dr Michael Gnant is Full Professor of Surgery at the Medical University of Vienna, Austria, where he also serves as President of the Austrian Breast & Colorectal Cancer Study Group. He is co-chairing and hosting the renowned St Gallen International Consensus Panel for Early Breast Cancer in Vienna since 2015.

Dr Gnant graduated in medicine in Vienna (1988) and subsequently specialized in surgery (1994) and surgical oncology. He also worked as a Visiting Scientist at the National Cancer Institute, National Institutes of Health, Bethesda, USA (1997–1999).

Dr Gnant’s research interests include several fields of surgical oncology, in particular breast and pancreatic cancer, immunotherapy, bone-targeted treatment for tumour micrometastases, tumor dormancy/quiescence and late relapse, pathway-directed therapies such as mTOR and CDK4/6 inhibition, SERDs, and he has been the Principal Investigator of many (N>30) clinical trials in these fields.

The author of more than 600 original peer-reviewed papers with an impact factor of 4,800 and an h-index of 90, Dr Gnant has presented over 1,000 lectures at national and international meetings. He is the recipient of multiple awards including the prestigious Claudia von Schilling Prize from the Medical University of Hannover, the Umberto Veronesi Lecture Award of Breast Surgery International, and a Corresponding Member of the Austrian Academy of Sciences. He holds an honorary MD degree of Sichuan University, Chengdu, China, and Honorary/Visiting Professorships of Tianjin Medical University, Jiaotong University Xi’an, and Nanjing Medical University in China. Repeatedly in recent years, he was among the most highly cited scientists worldwide.

Dr Gnant is involved in many scientific societies including ASCO, AACR, ACS, Breast International Group (BIG), EORTC, ESSO, EUSOMA and UICC. He served as an executive board member of BIG, is an independent reviewer and IDMC member for the EORTC, UICC and other international bodies, and is a scientific reviewer and process evaluator for the European Union. Dr Gnant is also Editor-in-Chief of BREAST CARE, and editorial board member and reviewer for many top-tier peer-reviewed journals including The Lancet, The New England Journal of Medicine, Journal of Clinical Oncology, and Annals of Oncology.

Univ.-Prof. Dr. Bob Djavan

Vienna / ATWien / AT

Management Board, Urology,

Bob Djavan is Professor of Urology Medical University Vienna (MUW) and New York University (NYU). Together with many other international leadership positions, he is the current Chairman of the Uroloy Center at Rudolfinerhaus, Vienna and Chairman of the GULF Uro-oncology Center in Bahrain. He is honorary Professor of the University of Budapest, Krakow, Bucharest and Pecs.

Prof. Djavan brings a wealth of academic and professional leadership experience from many parts of the world including academic fellowships in Dallas at University of Texas and John Hopkins School of Medicine, Baltimore. He served in numerous executive roles within international professional associations such as the European Association of Urology (EAU), the European Society of Oncological Urology, the WHO, the Vienna Urology Foundation, and many others. He is recipient of many national and international scientific awards as well as supporting grants both from academics and from industry. He is a well sought member of many international advisory boards both in academics as well as in industry. He serves on editorial boards and as reviewer of more than 10 international medical journals.

He was guest lecturer and congress chairman in numerous parts of the world.

As Chair VSCR Committee International Relations, Prof. Djavan will further organize/intensify the international network of VSCR and will further contribute to new academic and business relationships in many parts of the world.

Georg Schatzl

Vienna / AT

Urology